(Q37772183)

22 August 2017

1 reference

title

Pharmacogenetics and human genetic polymorphisms (English)

1 reference

22 August 2017

Ann K Daly

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

429

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

435-449

1 reference

Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-).

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Fourth-generation fluoroquinolones in tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

The Pennsylvania State University College of Medicine 1990 Bernard B. Brodie Lecture. Pharmacogenetics: past and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Drug reactions enzymes, and biochemical genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Studies on the induction of CO-binding pigments in liver microsomes by phenobarbital and 3-methylcholanthrene

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Position-specific oxygenation of benzo(a)pyrene by different forms of purified cytochrome P-450 from rabbit liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Identification of the primary gene defect at the cytochrome P450 CYP2D locus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

cDNA and amino acid sequences of two members of the human P450IIC gene subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Pharmacogenomics and individualized drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Significance of the minor cytochrome P450 3A isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Pharmacogenetics of opioids

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Codeine intoxication associated with ultrarapid CYP2D6 metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Pharmacogenomics of anticoagulants: steps toward personal dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Gilbert??s Syndrome and Drug Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Molecular mechanism of slow acetylation of drugs and carcinogens in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Diverse point mutations in the human gene for polymorphic N-acetyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

ABCB1 pharmacogenetics: progress, pitfalls, and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

New molecular insights into the mechanisms of cholestasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Impact of OATP transporters on pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Clinical consequences of ADRbeta2 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

From ligand binding to gene expression: new insights into the regulation of G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Influence of genetic polymorphisms in the beta2-adrenoceptor on desensitization in human lung mast cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genetic and clinical factors relating to warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Pharmacogenetic study of statin therapy and cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

An association study of 43 SNPs in 16 candidate genes with atorvastatin response

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genetics of the human renin angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Drug-induced hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

HLA association of amoxicillin-clavulanate--induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Co-amoxiclav jaundice: clinical and histological features and HLA class II association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

HLA-B locus in Caucasian patients with carbamazepine hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

The SLCO1B1*5 genetic variant is associated with statin-induced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Transporter pharmacogenetics and statin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Drug-induced long QT and torsade de pointes: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genome-wide association studies in pharmacogenomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genome-wide association studies for complex traits: consensus, uncertainty and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Cytochrome P450 epoxygenases as EDHF synthase(s).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Altered granulopoietic profile and exaggerated acute neutrophilic inflammation in mice with targeted deficiency in the sialyltransferase ST6Gal I

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Laying the foundations for personalized medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Pharmacogenetics of the major polymorphic metabolizing enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

The missing linkage: what pharmacogenetic associations are left to find in CYP3A?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Clinical implications of CYP3A polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

The increasing complexity of mercaptopurine pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genetic association studies in drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Pharmacogenomic insights into treatment and management of statin-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

The immunological and clinical spectrum of delayed drug-induced exanthems

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Transition from pharmaceutical to environmental research

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Risk of Stevens-Johnson syndrome and toxic epider mal necrolysis during first weeks of antiepileptic therapy: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20100522

21 January 2018

Identifiers

DOI

10.1042/BJ20100522

1 reference

22 August 2017

1 reference